Boris Engels

USPTO Granted Patents = 15 (Patent Applications = 12)

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Cambridge, MA (US) (2020)
Arlington, MA (US) (2019 - 2024)

Company Filing History:

University of Pennsylvania

patents

2 out of 1,206

Dana-farber-cancer Institute Inc.

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),

2. 12344651 - CD19 and CD22 chimeric antigen receptors and uses thereof (2025-07-01),

3. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),

4. 11999794 - Human mesothelin chimeric antigen receptors and uses thereof (2024-06-04),

5. 11981731 - Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy (2024-05-14),

6. 11975026 - CD19 and CD22 chimeric antigen receptors and uses thereof (2024-05-07),

7. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),

8. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),

9. 11578130 - Regulatable chimeric antigen receptor (2023-02-14),

10. 11413340 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2022-08-16),

11. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2021-06-08),

12. 10640569 - Human mesothelin chimeric antigen receptors and uses thereof (2020-05-05),

13. 10577417 - Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy (2020-03-03),

14. 10525083 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2020-01-07),

15. 10287354 - Regulatable chimeric antigen receptor (2019-05-14),

Title: Boris Engels: Pioneering Innovator in Technology

Introduction: Boris Engels, a distinguished inventor based in Arlington, MA (US), has carved a remarkable path in the realm of technology with his groundbreaking inventions.

Latest Patents: Boris Engels has 12 patents to his name, with his latest innovations including "Human mesothelin chimeric antigen receptors and uses thereof" and "Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy". These patents showcase his commitment to advancing medical technology for the betterment of society.

Career Highlights: Throughout his illustrious career, Boris has worked with renowned institutions such as Novartis AG and the University of Pennsylvania, where he has made significant contributions to the field of technology and healthcare. His relentless dedication to innovation has led to the development of cutting-edge solutions.

Collaborations: Boris Engels has collaborated with esteemed professionals in the industry, including Jennifer Brogdon and Huijuan Song. Together, they have synergized their expertise to create groundbreaking inventions that have the potential to revolutionize the way we approach healthcare and technology.

Conclusion: Boris Engels stands as a beacon of innovation, inspiring generations of inventors to push the boundaries of what is possible in technology. His unwavering commitment to creating a sustainable future through his inventions solidifies his position as a true trailblazer in the field.

This text is generated by artificial intelligence and may not be accurate.